Busulfan Pharmacokinetics in ADA SCID Gene Therapy
Busulfan (1,4-butanediol dimethanesulfonate) is a bifunctional alkylating agent that is cytotoxic to hematopoietic stem and progenitor cells (HSPC).1 Busulfan (BU) is widely used for cytoreduction (full or partial) in both myeloablative and reduced intensity allogeneic hematopoietic stem cell transplant (HSCT) conditioning regimens and prior to autologous gene therapy (GT). Appropriate BU dosing is critical to the success of HSCT, because low BU plasma exposure can result in engraftment failure and high BU exposure can increase regimen-related toxicity.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Kathryn L. Bradford, Siyu Liu, Maja Krajinovic, Marc Ansari, Elizabeth Garabedian, John Tse, Xiaoyan Wang, Kit L. Shaw, H. Bobby Gaspar, Fabio Candotti, Donald B. Kohn Source Type: research
More News: Biology | Gene Therapy | Genetics | Hematology | Stem Cell Therapy | Stem Cells | Toxicology | Transplants